AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34280472
Drug: Model including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Model including pretreatment miR‐185‐5p and miR‐425‐5p levels with mean parotid dose
Trial: 34280472
Drug: miR‐185‐5p and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miR‐185‐5p and miR‐425‐5p levels after 20 Gy with mean parotid dose
Trial: 37748693
Drug: Chemotherapy (platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (platinum-based doublet)
Trial: 34269160
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Hold)
Trial: 34163141
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tenofovir alafenamide tablets (test formulation)
Trial: 32228534
Drug: Health professionals'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health professionals' presentation of treatment arms
Trial: 32183810
Drug: Structured drug
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured drug review using the STRIP method assisted by a clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2)
Trial: 32183810
Drug: Structured drug
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured drug review
Trial: 32232885
Drug: Consolidated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidated therapy group (CTG) with balneotherapy and Chinese herbal medicine (CHM)
Trial: 32232885
Drug: Unconsolidated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconsolidated therapy group (UTG)
Trial: 34475270
Drug: Large monthly
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large monthly cash gift
Trial: 34475270
Drug: Nominal monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nominal monthly cash gift
Trial: 32482669
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy associated with supervised therapeutic exercises (STEP)
Trial: 32057962
Drug: 30-min plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-min plasma glucose >182 mg/dl
Trial: 34952123
Drug: Quetiapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (300 mg/day)
Trial: 34952123
Drug: Lithium (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (two different doses)
Trial: 34952123
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without lithium
Trial: 34154603
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg Capsiate (CAP)
Trial: 32757317
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU daily of cholecalciferol
Trial: 32757317
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU daily of cholecalciferol (Control)
Trial: 35490873
Drug: GDMT titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDMT titrated to achieve NT-proBNP <1000 pg/mL
Trial: 32965802
Drug: Low-dose furosemide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose furosemide (2.5 mg/kg)
Trial: 32965802
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (5 mg/kg)
Trial: 34984794
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg once daily for 8 days
Trial: 33657998
Drug: Mulligan Manual
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulligan Manual Therapy (MMT) and exercise
Trial: 35725141
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity promotion text messages
Trial: 35725141
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1 neutral message related to general health information weekly)
Trial: 36111824
Drug: iN2L tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iN2L tablets and access to Alzheimer's Association supportive programs
Trial: 34511168
Drug: Alfacalcidol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (0.25 μg/d) for 4 weeks
Trial: 34511168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vitamin C, rutin tablets, dipyridamole, cimetidine, calcium supplements, glucocorticoids)
Trial: 32955023
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Acetaminophen + Ibuprofen)
Trial: 34010531
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment target (systolic blood pressure <120 mm Hg)
Trial: 34010531
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment target (systolic blood pressure <140 mm Hg)
Trial: 32621071
Drug: 1064 mg
RxNorm normalized name: Aristada 1064 MG in 3.9 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064 mg q8wk
Trial: 32621071
Drug: 882 mg
RxNorm normalized name: Aristada 882 MG in 3.2 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 882 mg q6wk
Trial: 32621071
Drug: 441 mg
RxNorm normalized name: Aristada 441 MG in 1.6 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 441 mg q4wk
Trial: 35017008
Drug: Bicalutamide 150mg
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150mg daily
Trial: 33512329
Drug: Therapist-guided, VR-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided, VR-based cognitive training intervention combined with treatment as usual
Trial: 33512329
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual without cognitive training
Trial: 36228297
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered during the induction of anesthesia
Trial: 36506904
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric Carboxymaltose (FCM) 1000 mg IV as a single dose
Trial: 36506904
Drug: Ferrous Sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous Sulphate (FS) tablets 120 mg iron daily, taken twice daily
Trial: 35869710
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia
Trial: 32506827
Drug: TD-0714 (50-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-0714 (50-600 mg single ascending dose)
Trial: 32506827
Drug: TD-0714 (10-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-0714 (10-200 mg q.d. for 14 days)
Trial: 36038614
Drug: Experimental videos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental videos reviewing preparation and administration of medications used during ovarian stimulation
Trial: 33666378
Drug: docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel plus curcumin (6 g/d for 7 days every 3 weeks)
Trial: 37399894
Drug: Niraparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (200 mg orally) plus abiraterone acetate (AAP) (1000 mg/10 mg orally)
Trial: 37399894
Drug: Niraparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (200 mg orally) plus AAP (1000 mg/10 mg orally)
Trial: 32949382
Drug: Practical Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practical Body Image therapy (PBI) with mirror exposure (ME) as an adjuvant to treatment as usual (TAU)
Trial: 35218626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acupuncture and core muscle training
Trial: 36432599
Drug: Oxxynea® (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxxynea® (450 mg)
Trial: 32886178
Drug: Intranasal remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal remimazolam (10, 20, and 40 mg)
Trial: 32886178
Drug: Intranasal remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal remimazolam solution (higher doses)
Trial: 32886178
Drug: Intranasal remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal remimazolam (10 to 40 mg)
Trial: 32886178
Drug: Intranasal remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal remimazolam
Trial: 32886178
Drug: Intravenous remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous remimazolam (4 mg)
Trial: 32885440
Drug: Probiotic capsule
RxNorm normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsule + placebo of prebiotic
Trial: 35758855
Drug: Roselle drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roselle drink (200 ml)
Trial: 34121642
Drug: Icelandic yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icelandic yogurt (IR; n 15, 18 g of protein)
Trial: 34121642
Drug: Iso-energetic placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso-energetic placebo (PR; n 15, 0 g protein)
Trial: 32066607
Drug: OHP (Optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHP (Optimal Health Programme) plus treatment as usual
Trial: 33142545
Drug: Selenium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched yeast (SY) supplementation at 0.1, 0.2, 0.3, or 0.4 mg/kg
Trial: 33142545
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite (SS) supplementation at 0.3 mg/kg
Trial: 35124285
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (pronator teres rerouting, FCU transfer to ECRB, fractional lengthening)
Trial: 32304832
Drug: Ragweed SLIT-tablet
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed SLIT-tablet (12 Amb a 1-Unit)
Trial: 34847501
Drug: Risperidone ISM®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone ISM® 75 or 100 mg once-monthly intramuscular injections for 12 months
Trial: 34586227
Drug: Panretinal photocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panretinal photocoagulation with ranibizumab injections
Trial: 33913639
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g)
Trial: 33845034
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity
Trial: 36113394
Drug: Sertraline or
RxNorm normalized name: sertraline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline or interpersonal psychotherapy for 14 weeks (T2)
Trial: 36113394
Drug: Treatment received
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment received (Sertraline or interpersonal psychotherapy)
Trial: 34212560
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine plus intravenous remifentanil (DEX-REMI group)
Trial: 34212560
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil only (REM group)
Trial: 35350988
Drug: Levosimendan +
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan + Shenfu injection (SFI)
Trial: 33823265
Drug: Lower extremity
RxNorm normalized name: lymphedema garments, lower extremity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower extremity intermittent negative pressure (INP) of -40 mm Hg for one hour twice daily for 24 weeks
Trial: 33871363
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture (L. plantarum PBS067, L. reuteri PBS072, L. rhamnosus LRH020) for 56 days
Trial: 36040071
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B gel (LAmB gel) for 28 days
Trial: 36040071
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for 28 days
Trial: 36040071
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B gel (LAmB gel) for 56 days
Trial: 36071664
Drug: Tablet for
RxNorm normalized name: TABLET FOR SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for multimodal learning
Trial: 36071664
Drug: Nurse explanation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse explanation on home self‐injection of enoxaparin sodium (Control)
Trial: 33787151
Drug: Yangxue Qingnao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxue Qingnao Granules combined with conventional anti-hypertensive agents
Trial: 34862359
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (Tx0) for 3 weeks
Trial: 33054008
Drug: Traditional conservative
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional conservative therapy and different wavelengths laser therapy (LT) course
Trial: 33054008
Drug: Traditional conservative
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional conservative therapy and intravenous laser blood irradiation (ILBI) (λ - 635 nm)
Trial: 33054008
Drug: Traditional conservative
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional conservative therapy only
Trial: 35710594
Drug: Established antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established antihypertensive therapy
Trial: 35730245
Drug: EsoduoⓇ (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EsoduoⓇ (esomeprazole 20 mg with sodium bicarbonate 800 mg)
Trial: 35730245
Drug: NexiumⓇ (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NexiumⓇ (esomeprazole 20 mg)
Trial: 34124929
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Processing Therapy (CPT)
Trial: 32198939
Drug: Branebrutinib (0.3-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branebrutinib (0.3-30 mg for SAD; 0.3-10 mg for JMAD)
Trial: 32198939
Drug: Branebrutinib (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branebrutinib (daily for 14 days in MAD)
Trial: 32198939
Drug: Branebrutinib (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branebrutinib (single 10 mg dose)
Trial: 35869266
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy then momelotinib
Trial: 32158202
Drug: Progressive Resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Resistance Training (PRT) - 9-week program, twice a week
Trial: 34397698
Drug: Combined Naikan
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Naikan therapy (NT) and Morita therapy (MT) for 7 consecutive weeks
Trial: 34397698
Drug: Normal medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal medical treatments without NT and MT
Trial: 36173238
Drug: Insulin-only configuration
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-only configuration of the iLet® bionic pancreas (BP)
Trial: 35337193
Drug: Development and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development and Well-Being Assessment (DAWBA) as an adjunct to referral letters
Trial: 35461285
Drug: Antisecretory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisecretory factor (Salovum®) as a food supplement
Trial: 33596852
Drug: Cranberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry beverage consumed daily for 24 weeks
Trial: 32513257
Drug: Topical Timoptic-XE®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Timoptic-XE® (timolol maleate ophthalmic gel forming solution)
Trial: 36917429
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site reactions
Trial: 33001232
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of pioglitazone for 16 weeks
Trial: 33247012
Drug: 99DOTS-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99DOTS-based treatment supervision
Trial: 34107933
Drug: Oral rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehabilitation procedures
Trial: 34107933
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral rehabilitation during the study period)
Trial: 34277476
Drug: M+P (Miltefosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M+P (Miltefosine 50 mg BID and Pentoxifylline 400 mg TID)
Trial: 34277476
Drug: A+P (Antimonials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A+P (Antimonials 20 mg Sb+V/kg/day IV and Pentoxifylline 400 mg TID)
Trial: 34277476
Drug: Treatment comparison
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment comparison (M+P vs A+P)
Trial: 36112655
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg Se methionine
Trial: 36112655
Drug: 0.6, 0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6, 0.3, and 0.0 mg/kg Se methionine
Trial: 32695229
Drug: Resveratrol 100
RxNorm normalized name: resveratrol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 100 mg capsule daily for 3 months
Trial: 32645251
Drug: 1% Sandalore®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Sandalore® solution
Trial: 33243284
Drug: M. communis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. communis preparation in addition to conventional therapy
Trial: 39186268
Drug: Modified directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified directly observed therapy
Trial: 32649736
Drug: GLS4 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS4 (120 mg) and ritonavir (100 mg)
Trial: 32649736
Drug: GLS4 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS4 (240 mg) and ritonavir (100 mg)
Trial: 36122259
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection into coracohumeral ligament (CHL) and inferior glenohumeral capsule (IGHC)
Trial: 36122259
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection into posterior glenohumeral recess (PGHR)
Trial: 34429340
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate (240 mg)
Trial: 34321304
Drug: Dural sealant
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dural sealant patch (DSP)
Trial: 37480877
Drug: Atrial shunt
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial shunt therapy (Corvia Medical, Inc IASD System II)
Trial: 37480877
Drug: Patch-detected AF
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch-detected AF during follow-up
Trial: 616168499
Drug: Nefopam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (0.3 mg/kg bolus followed by continuous infusion at 65 micro g/kg/h)
Trial: 616168499
Drug: Ketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.3 mg/kg bolus followed by continuous infusion at 180 micro g/kg/h)